HFOV Charges and Reimbursement: Practices and Experience

Introduction Since its availability in the late 1960's, mechanical ventilation has led to dramatic improvements in treating infants with hyaline membrane disease (HMD). However, in today's economic environment, with each technological step taken, comes the justification of costs against the reimbursement attainable. High frequency oscillatory ventilation (HFOV) is one of those technologies whose charge and reimbursement components has not been systematically reviewed.